#United States #San Diego #Mallinckrodt #TERLIVAZ #Digestive Disease Week

Mallinckrodt to Present Findings on TERLIVAZ® at DDW 2025

Mallinckrodt plc, an established name in the pharmaceutical industry, is preparing to unveil compelling new findings regarding TERLIVAZ® (terlipressin) at the upcoming Digestive Disease Week (DDW) 2025 in San Diego, California, from May 3 to 6. This prestigious event marks a significant gathering of experts in gastroenterology and hepatology, providing a platform for discussing advancements in treatment options for digestive diseases.

TERLIVAZ holds a unique position as the sole FDA-approved treatment aimed at improving kidney function in adults diagnosed with hepatorenal syndrome (HRS) exhibiting rapid declines in kidney performance. Marked by its acute and potentially life-threatening nature, HRS is a condition that necessitates immediate hospitalization, and evidence suggests that the number of individuals affected is on the rise.

Recent statistics estimate that HRS-AKI, a specific type of this condition, impacts over 42,000 people in the U.S. annually, with its severity emphasizing the pressing need for effective therapeutic interventions. The rising hospitalization rates associated with HRS-derived maladies underscore the urgency for medical advancements such as those presented by Mallinckrodt.

During DDW, the company will feature four posters and one oral presentation detailing real-world evidence analyses regarding the impact of TERLIVAZ on patients suffering from HRS. Noteworthy abstracts to be presented include studies evaluating the comparative outcomes of TERLIVAZ treatment versus traditional therapeutic approaches, informing practitioners on best practices for managing HRS-AKI.

Key Presentations at DDW:
1. Oral Session: Treatment and Outcomes of Terlipressin in Hospitalized Adults with HRS-AKI - This session will delve into real-world patient outcomes based on their transplant waitlist status, presented by Kavish R. Patidar.

2. Poster Session: A Comparative Analysis of Real-World HRS-AKI Treatment and Outcomes in the UK and US - Presenter Stevan A. Gonzalez will share insights from the clinical data comparing patient responses across distinct healthcare systems.

3. Additional posters will focus on comparing treatments among patients with alcohol-related liver disease and the efficacy of TERLIVAZ versus placebo in acute kidney injury scenarios.

Peter Richardson, Executive Vice President and Chief Scientific Officer at Mallinckrodt, expressed enthusiasm about the opportunity to connect with peers and share vital data. “We are excited to showcase how TERLIVAZ affects treatment outcomes in real-world scenarios,” he stated. This commitment to research exemplifies Mallinckrodt's dedication to enhancing patient care and addressing critical health challenges.

While the findings may offer innovative therapeutic pathways, it’s crucial for healthcare providers to understand the safety profile of TERLIVAZ. The drug includes a boxed warning regarding serious risks, such as respiratory failure, emphasizing careful patient monitoring and consideration of pre-existing conditions that may exacerbate these risks.

The Significance of HRS

HRS manifests in two primary forms: the rapidly progressing variant leading to acute kidney failure and the chronic type that develops gradually. Patients suffering from HRS-AKI experience drastic symptoms that can result in significantly reduced survival rates if left untreated, prompting the need for immediate medical attention and intervention.

With a highlighted focus on HRS treatment and the potential of TERLIVAZ, DDW 2025 serves not only as an informative meeting for practitioners but as a pivotal moment in advancing clinical practices concerning hepatic illnesses. For anyone involved in the healthcare and pharmaceutical realms, these presentations will provide invaluable insights into evolving treatment landscapes.

About Mallinckrodt
Mallinckrodt operates internationally, with a commitment to improving medical practices and patient outcomes, focusing on autoimmune and rare diseases within various specialty domains. Their track record in developing essential therapies positions them as a leader in the pharmaceutical space.

As DDW approaches, the anticipation surrounding Mallinckrodt’s presentations is palpable, with the potential for significant advancements in understanding and treating one of the most complex and critical health conditions affecting the liver and kidneys.